Pfizer Inc. $PFE Stock Holdings Boosted by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 21,615,496 shares of the biopharmaceutical company’s stock after acquiring an additional 2,743,107 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Pfizer were worth $547,737,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Martingale Asset Management L P lifted its position in shares of Pfizer by 313.1% during the 1st quarter. Martingale Asset Management L P now owns 525,188 shares of the biopharmaceutical company’s stock valued at $13,308,000 after acquiring an additional 398,059 shares during the last quarter. Candriam S.C.A. lifted its position in shares of Pfizer by 292.8% during the 1st quarter. Candriam S.C.A. now owns 1,659,600 shares of the biopharmaceutical company’s stock valued at $42,054,000 after acquiring an additional 1,237,099 shares during the last quarter. Banco BTG Pactual S.A. acquired a new stake in shares of Pfizer during the 1st quarter valued at $2,541,000. Dorsey & Whitney Trust CO LLC lifted its position in shares of Pfizer by 10.7% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 80,973 shares of the biopharmaceutical company’s stock valued at $2,052,000 after acquiring an additional 7,814 shares during the last quarter. Finally, GM Advisory Group LLC lifted its position in shares of Pfizer by 5.7% during the 1st quarter. GM Advisory Group LLC now owns 30,434 shares of the biopharmaceutical company’s stock valued at $771,000 after acquiring an additional 1,629 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $25.8250 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The stock has a fifty day moving average of $24.70 and a 200-day moving average of $24.42. The firm has a market capitalization of $146.83 billion, a P/E ratio of 13.74, a PEG ratio of 0.92 and a beta of 0.52.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company earned $0.60 earnings per share. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. HSBC cut their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Redburn Atlantic reduced their target price on Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Bank of America increased their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Wolfe Research increased their target price on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.